Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
Division of Medical Oncology and Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
Curr Oncol. 2021 Jan 6;28(1):278-282. doi: 10.3390/curroncol28010032.
Patients with cancer are more vulnerable to severe COVID-19. As a result, routine SARS-CoV-2 testing of asymptomatic patients with cancer is recommended prior to treatment. However, there is limited evidence of its clinical usefulness. The objective of this study is to evaluate the value of routine testing of asymptomatic patients with cancer. Asymptomatic patients with cancer attending Odette Cancer Centre (Toronto, ON, Canada) were tested for SARS-CoV-2 prior to and during treatment cycles. Results were compared to positivity rates of SARS-CoV-2 locally and provincially. All 890 asymptomatic patients tested negative. Positivity rates in the province were 1.5%, in hospital were 1.0%, and among OCC's symptomatic cancer patients were 0% over the study period. Given our findings and the low SARS-CoV-2 community positivity rates, we recommend a dynamic testing model of asymptomatic patients that triggers testing during increasing community positivity rates of SARS-CoV-2.
癌症患者更容易受到严重 COVID-19 的影响。因此，建议在治疗前对无症状癌症患者进行常规 SARS-CoV-2 检测。然而，其临床实用性的证据有限。本研究的目的是评估对无症状癌症患者进行常规检测的价值。在多伦多安大略癌症中心（加拿大安大略省多伦多市）就诊的无症状癌症患者在治疗周期前后接受了 SARS-CoV-2 检测。结果与当地和省级 SARS-CoV-2 的阳性率进行了比较。所有 890 名无症状患者的检测结果均为阴性。在本研究期间，该省的阳性率为 1.5%，医院为 1.0%，OCC 的有症状癌症患者为 0%。鉴于我们的发现和 SARS-CoV-2 社区低阳性率，我们建议对无症状患者采用动态检测模型，根据 SARS-CoV-2 社区阳性率的增加触发检测。
